/
Cardiovascular
Coronary Artery Disease
55
Pipeline Programs↗
205
Active Trials↗
73
Companies Involved↗
Coronary Artery Disease is a moderately active landscape with 55 programs across 73 companies. The most active players are Haisco Pharmaceutical Group Co., Ltd., Hexun Biosciences Co., LTD., Ribocure Pharmaceuticals AB. 12 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical39
Phase 23
Phase 312
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
42 of 47 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 47 classified programs, each share of the total. Modality classified for 93% of 55 pipeline programs.
Analysis
Trial Status
444
clinical trials
Completed167 · 38%
Recruiting105 · 24%
Unknown status51 · 11%
Not yet recruiting50 · 11%
Active, not recruiting43 · 10%
Terminated14 · 3%
Other14 · 3%
Clinical Trials
Trial Activity
444 trials
Real-World Outcomes of Drug-Coated Balloon Angioplasty in Coronary Artery Disease: A Multicenter Ambispective Cohort Study
Recruiting·—·N/A·NCT07875088·2,000 enrolled
A GLOBAL, MULTICENTER, PROSPECTIVE, REAL WORLD OBSERVATIONAL STUDY FOR LEFT MAIN DISEASE TREATMENT
Recruiting·—·N/A·NCT01341327·10,000 enrolled
Page 1 of 30
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)